Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure

被引:38
|
作者
Perianayagam, MC [1 ]
Murray, SL [1 ]
Balakrishnan, VS [1 ]
Guo, DQ [1 ]
King, AJ [1 ]
Pereira, BJG [1 ]
Jaber, BL [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Nephrol, Tupper Res Inst, Dept Med, Boston, MA 02111 USA
来源
关键词
D O I
10.1067/mlc.2000.109318
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Apoptosis, or programmed cell death, is an active form of cell death that is initiated by a number of stimuli and is intricately regulated, Apoptosis in both excessive and reduced amounts has pathophysiologic implications. Accelerated programmed cell death has been observed in leukocytes among patients with chronic renal failure (CRF). This has been ascribed in part to the retention of uremic toxins. The Fas/Fas ligand (FasL) system is a key regulatory apoptotic pathway, Membrane-bound Fas is a cell-surface receptor that transduces apoptosis after interaction with membrane-bound or soluble FasL (sFasL). By contrast, soluble Fas (sFas) binds sFasL and inhibits its activity. In an attempt to examine the balance between these soluble factors in uremia, we measured soluble sFas and sFasL levels in the serum of healthy control subjects and patients with various degrees of CRF and examined the distribution of the various molecular mass fractions of these proteins in uremic serum. In brief, serum was obtained from 15 healthy volunteers, 17 patients with CRF, 11 patients undergoing maintenance hemodialysis (HD), and 7 patients undergoing peritoneal dialysis (PD). Serum sFas and sFasL were measured by enzyme-linked immunosorbent assay, and their molecular distribution was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot. Compared with results in healthy control subjects, sFas levels were significantly higher in patients with CRF and in patients undergoing dialysis. There was a significant inverse correlation between sFas levels and creatinine clearance. Serum sFasL levels were not different among the four groups. However, the sFas-to-sFasL ratio was significantly lower in healthy control subjects as compared with patients with CRF and patients undergoing dialysis. Immunoblots and densitometric analyses of sFas and sFasL depicted a known 48-kd sFas, a known 27-kd sFasL, and a 60-kd sFas-sFasL protein aggregate signal. In conclusion, serum sFas levels are increased in patients with various degrees of CRF and may bind circulating sFasL, thereby minimizing mediation of cellular apoptosis.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [21] Evaluation of CD95 (APO-1/FAS) and the CD95 ligand in acute myelogenous leukemia
    Mestice, A
    Specchia, G
    Coppi, MR
    Palumbo, G
    Carluccio, P
    Attolico, I
    Quarta, A
    Liso, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 74 - 74
  • [22] Molecular cloning, characterization, and expression of porcine fas ligand (CD95 ligand)
    Muneta, Y
    Shimoji, Y
    Inumaru, S
    Mori, Y
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (05): : 305 - 312
  • [23] Fas-ligand (CD95 ligand) controls angiogenesis beneath the retina
    Kaplan, HJ
    Leibole, MA
    Tezel, T
    Ferguson, TA
    FASEB JOURNAL, 1999, 13 (04): : A523 - A523
  • [24] Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes
    Munker, R
    Midis, G
    OwenSchaub, L
    Andreff, M
    LEUKEMIA, 1996, 10 (09) : 1531 - 1533
  • [25] Posttranscriptional control of the apoptosis-inducing Fas (CD95) ligand
    Brunner, T
    TISSUE ANTIGENS, 2004, 64 (04): : 341 - 341
  • [26] Soluble Fas (CD95/Apo-1), Soluble Fas Ligand, and Activated Caspase 3 in the Cerebrospinal Fluid of Infants with Posthemorrhagic and Nonhemorrhagic Hydrocephalus
    Ursula Felderhoff-Mueser
    Christoph Bührer
    Peter Groneck
    Michael Obladen
    Peter Bartmann
    Axel Heep
    Pediatric Research, 2003, 54 : 659 - 664
  • [27] Death the Fas way: regulation and pathophysiology of CD95 and its ligand
    Sharma, K
    Wang, RX
    Zhang, LY
    Yin, DL
    Luo, XY
    Solomon, JC
    Jiang, RF
    Markos, K
    Davidson, W
    Scott, DW
    Shi, YF
    PHARMACOLOGY & THERAPEUTICS, 2000, 88 (03) : 333 - 347
  • [28] Fas (CD95, Apo-1) Ligand Gene Transfer
    Salah-Eddine Lamhamedi-Cherradi
    Youhai Chen
    Journal of Clinical Immunology, 2001, 21 : 24 - 29
  • [29] Fas (CD95, Apo-1) ligand gene transfer
    Lamhamedi-Cherradi, SE
    Chen, YH
    JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (01) : 24 - 29
  • [30] Fas (CD95/Apo-1)/Fas Ligand Expression in Neonates with Pontosubicular Neuron Necrosis
    Frank K H Van Landeghem
    Ursula Felderhoff-Mueser
    Axel Moysich
    Christine Stadelmann
    Michael Obladen
    Wolfgang Brück
    Christoph Bührer
    Pediatric Research, 2002, 51 : 129 - 135